Treatment of mouse glioblastoma microglia with both recombinant and glioma-released CXCL16 increased the expression of anti-inflammatory genes ARG1, CHIL3, RETNLA and CD163 that was impaired by anti-CXCL16 antibodies. This evidence concerns the gene CXCL16 and central nervous system cancer.